Avalo Therapeutics, Inc.

AVTX

Healthcare|Biotechnology|US

$6.93

+0.30 (+4.52%)

DCF Value

$0.99

Tangible Book / Share

$7.74

Cash / Share

$7.14

Clinical Trials (20)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT02777931 Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD	Attention Deficit Disorder With Hyperactivity	P2P3	Completed	101	RCT, Double-blind	NFC-1, Placebo
NCT06603077 A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa	Hidradenitis Suppurativa	P2	Completed	253	RCT, Double-blind	AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo
NCT03265119 PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations	Attention Deficit Hyperactivity Disorder	P2	Completed	69	RCT, Double-blind	AEVI-001, Placebo
NCT03609619 PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations	Attention Deficit Hyperactivity Disorder	P2	Completed	109	RCT, Double-blind	AEVI-001, Placebo
NCT05288504 A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.	Non-Eosinophilic Asthma	P2	Completed	91	RCT, Double-blind	AVTX-002, Placebo
NCT01941043 A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment	Major Depressive Disorder	P2	Completed	1,357	RCT, Double-blind	CERC-301
NCT01597349 Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection	Acute Cough	P2	Completed	208	RCT, Double-blind	FP01
NCT02459236 A Study of Intermittent Doses of CERC-301 in MDD	Major Depressive Disorder	P2	Completed	115	RCT, Double-blind	CERC-301, Placebo
NCT04412057 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury	COVID-19 Pneumonia, Acute Lung Injury	P2	Completed	88	RCT, Double-blind	CERC-002, Placebo
NCT01703923 An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough	Chronic Refractory Cough	P2	Completed	83	RCT, Double-blind	FP01, placebo
NCT02468414 TARGTEPO Treatment for Anemia in PD US Trial	Anemia of End Stage Renal Disease	P2	Terminated	3	Open-label	MDGN201 TARGTEPO, MDGN201 TARGTEPO
NCT02895906 Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions	22q11.2 Deletion Syndrome	P1	Completed	2	Open-label	NFC-1
NCT04671251 Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma	Multiple Myeloma	P1	Completed	13	Open-label	AEVI-007
NCT01579526 A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers	Healthy	P1	Completed	40	RCT, Open-label	FP01
NCT03169894 Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis	Crohn Disease, Ulcerative Colitis	P1	Terminated	8	Open-label	MDGN-002
NCT02286817 Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder	Attention-deficit Hyperactivity Disorder (ADHD)	P1	Completed	30	Open-label	NFC-1
NCT04994002 A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations	Lymphatic Malformation	P1	Withdrawn	—	Open-label	CERC-006
NCT03006367 Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD	Attention Deficit Disorder With Hyperactivity	P1	Completed	32	Open-label	NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
NCT02811211 A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD	Attention Deficit Disorder With Hyperactivity		Completed	1,894	—	—
NCT03233867 A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations	Attention Deficit Hyperactivity Disorder		Completed	2,503	—	—